Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure

Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC). During the last two decades, with the use of currently available anti-HBV therapies (lamivudine, entecavir and tenofovir...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinn, Brianna J, Martin, Aaron, Coben, Robert M, Conn, Mitchell I, Prieto, Jorge, Kroop, Howard, DiMarino, Anthony J, Hann, Hie-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354125/
https://www.ncbi.nlm.nih.gov/pubmed/30705719
http://dx.doi.org/10.4254/wjh.v11.i1.65

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354125/
https://www.ncbi.nlm.nih.gov/pubmed/30705719
http://dx.doi.org/10.4254/wjh.v11.i1.65

Ejemplares similares